Symbols / RZLT
RZLT Chart
About
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 337.33M |
| Enterprise Value | 213.82M | Income | -84.23M | Sales | — |
| Book/sh | 1.23 | Cash/sh | 1.39 | Dividend Yield | — |
| Payout | 0.00% | Employees | 75 | IPO | — |
| P/E | — | Forward P/E | -4.86 | PEG | — |
| P/S | — | P/B | 2.86 | P/C | — |
| EV/EBITDA | -2.42 | EV/Sales | — | Quick Ratio | 13.95 |
| Current Ratio | 14.18 | Debt/Eq | 1.00 | LT Debt/Eq | — |
| EPS (ttm) | -0.93 | EPS next Y | -0.73 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-12 | ROA | -44.09% |
| ROE | -74.02% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 95.70M |
| Shs Float | 65.54M | Short Float | 31.42% | Short Ratio | 4.29 |
| Short Interest | — | 52W High | 11.46 | 52W Low | 1.07 |
| Beta | 0.51 | Avg Volume | 7.31M | Volume | 1.23M |
| Target Price | $4.75 | Recom | Buy | Prev Close | $3.61 |
| Price | $3.52 | Change | -2.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.75
Mean price target
2. Current target
$3.53
Latest analyst target
3. DCF / Fair value
$-8.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.53
Low
$2.00
High
$6.00
Mean
$4.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-08 | main | Wedbush | Neutral → Neutral | $2 |
| 2026-01-08 | reit | BTIG | Buy → Buy | $5 |
| 2025-12-12 | main | Guggenheim | Buy → Buy | $6 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-11-20 | reit | BTIG | Buy → Buy | $17 |
| 2025-10-29 | main | Citizens | Market Outperform → Market Outperform | $17 |
| 2025-09-22 | reit | Guggenheim | Buy → Buy | $15 |
| 2025-09-19 | main | Maxim Group | Buy → Buy | $20 |
| 2025-09-18 | reit | BTIG | Buy → Buy | $17 |
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-13 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-13 | main | JMP Securities | Market Outperform → Market Outperform | $9 |
| 2025-02-10 | reit | Guggenheim | Buy → Buy | — |
| 2025-02-05 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-11-05 | init | Wedbush | — → Outperform | $12 |
| 2024-08-06 | main | Maxim Group | Buy → Buy | $10 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-07-17 | init | BTIG | — → Buy | $13 |
- Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround - Yahoo Finance Mon, 15 Dec 2025 08
- Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - GlobeNewswire Mon, 09 Feb 2026 20
- RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know - Zacks Investment Research Wed, 17 Dec 2025 08
- $RZLT stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 30 Dec 2025 08
- Rezolute (Nasdaq: RZLT) sets December 2025 topline for Phase 3 sunRIZE; cash $152.2M - Stock Titan hu, 06 Nov 2025 08
- Craig-Hallum Remains a Hold on Rezolute (RZLT) - The Globe and Mail Wed, 18 Feb 2026 08
- Rezolute (NASDAQ:RZLT) Shares Down 3.8% - What's Next? - MarketBeat Fri, 30 Jan 2026 08
- Rezolute, Inc. Stock (RZLT) Opinions on Upcoming Clinical Data Release | RZLT Stock News - Quiver Quantitative Sun, 07 Dec 2025 08
- Rezolute (Nasdaq: RZLT) Phase 3 sunRIZE in HI Misses Primary, Secondary Goals - Stock Titan hu, 11 Dec 2025 08
- Rezolute (RZLT): Assessing Valuation After a Year of Strong Share Price Gains - Yahoo Finance hu, 11 Dec 2025 08
- $RZLT stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Wed, 10 Dec 2025 08
- RZLT SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - GlobeNewswire Sun, 15 Feb 2026 13
- Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism Trial - Yahoo Finance Sun, 14 Dec 2025 08
- Insider Purchase: Director at $RZLT Buys 5,650 Shares - Quiver Quantitative Wed, 17 Dec 2025 08
- Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy - Yahoo Finance Wed, 29 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5650 | 9548 | — | Purchase at price 1.69 per share. | HOGENHUIS WLADIMIR | Director | — | 2025-12-16 00:00:00 | D |
| 1 | 28000 | 47600 | — | Purchase at price 1.70 per share. | ROBERTS BRIAN KENNETH | Officer | — | 2025-12-16 00:00:00 | D |
| 2 | 32000 | 50880 | — | Purchase at price 1.59 per share. | ELAM NEVAN C | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 3 | 45000 | 79578 | — | Purchase at price 1.77 - 1.79 per share. | EVANS DARON | Chief Financial Officer | — | 2025-12-15 00:00:00 | D/I |
| 4 | 12100 | 19599 | — | Purchase at price 1.60 - 1.62 per share. | KARNAWAT SUNIL RATILAL | Officer | — | 2025-12-15 00:00:00 | D |
| 5 | 317000 | — | — | Stock Award(Grant) at price 0.00 per share. | ELAM NEVAN C | Chief Executive Officer | — | 2025-11-19 00:00:00 | D |
| 6 | 21000 | — | — | Stock Award(Grant) at price 0.00 per share. | LABRUCHERIE GILBERT M JR | Director | — | 2025-11-19 00:00:00 | D |
| 7 | 107000 | — | — | Stock Award(Grant) at price 0.00 per share. | EVANS DARON | Chief Financial Officer | — | 2025-11-19 00:00:00 | D |
| 8 | 21000 | — | — | Stock Award(Grant) at price 0.00 per share. | KREHER NERISSA C | Director | — | 2025-11-19 00:00:00 | D |
| 9 | 21000 | — | — | Stock Award(Grant) at price 0.00 per share. | HOGENHUIS WLADIMIR | Director | — | 2025-11-19 00:00:00 | D |
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -79.86M | -67.48M | -55.95M | -41.52M |
| TotalUnusualItems | -2.91M | -5.00K | 2.28M | 1.79M |
| TotalUnusualItemsExcludingGoodwill | -2.91M | -5.00K | 2.28M | 1.79M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -74.41M | -68.46M | -51.79M | -41.06M |
| ReconciledDepreciation | 31.00K | 36.00K | 30.00K | 13.00K |
| EBITDA | -79.86M | -70.39M | -55.96M | -39.24M |
| EBIT | -79.89M | -70.42M | -55.99M | -39.25M |
| NetInterestIncome | 5.48M | 4.87M | 4.21M | -1.73M |
| InterestExpense | 0.00 | 1.81M | 375.00K | |
| InterestIncome | 5.48M | 4.87M | 4.21M | 80.00K |
| NormalizedIncome | -74.41M | -65.55M | -51.78M | -43.34M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -74.41M | -68.46M | -51.79M | -41.06M |
| TotalExpenses | 79.89M | 70.42M | 55.99M | 41.61M |
| TotalOperatingIncomeAsReported | -79.89M | -70.42M | -55.99M | -41.84M |
| DilutedAverageShares | 76.00M | 51.47M | 51.19M | 19.49M |
| BasicAverageShares | 76.00M | 51.47M | 51.19M | 18.20M |
| DilutedEPS | -0.98 | -1.33 | -1.01 | -2.32 |
| BasicEPS | -0.98 | -1.33 | -1.01 | -2.26 |
| DilutedNIAvailtoComStockholders | -74.41M | -68.46M | -51.79M | -45.13M |
| AverageDilutionEarnings | 0.00 | -4.07M | 0.00 | |
| NetIncomeCommonStockholders | -74.41M | -68.46M | -51.79M | -41.06M |
| NetIncome | -74.41M | -68.46M | -51.79M | -41.06M |
| NetIncomeIncludingNoncontrollingInterests | -74.41M | -68.46M | -51.79M | -41.06M |
| NetIncomeContinuousOperations | -74.41M | -68.46M | -51.79M | -41.06M |
| PretaxIncome | -74.41M | -68.46M | -51.79M | -41.06M |
| OtherIncomeExpense | -2.91M | -5.00K | 2.28M | 1.79M |
| OtherNonOperatingIncomeExpenses | 515.00K | |||
| SpecialIncomeCharges | 0.00 | -1.77M | 0.00 | |
| OtherSpecialCharges | 1.77M | -515.00K | ||
| GainOnSaleOfSecurity | -2.91M | -5.00K | 4.05M | 1.79M |
| NetNonOperatingInterestIncomeExpense | 5.48M | 4.87M | 4.21M | -1.73M |
| InterestExpenseNonOperating | 0.00 | 1.81M | 375.00K | |
| InterestIncomeNonOperating | 5.48M | 4.87M | 4.21M | 80.00K |
| OperatingIncome | -79.89M | -70.42M | -55.99M | -41.61M |
| OperatingExpense | 79.89M | 70.42M | 55.99M | 41.61M |
| OtherOperatingExpenses | -231.00K | -515.00K | ||
| ResearchAndDevelopment | 61.53M | 55.74M | 43.81M | 32.49M |
| SellingGeneralAndAdministration | 18.37M | 14.68M | 12.18M | 9.36M |
| GeneralAndAdministrativeExpense | 18.37M | 14.68M | 12.18M | 9.36M |
| OtherGandA | 18.37M | 14.68M | 12.18M | 9.36M |
| SalariesAndWages | 4.89M | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 87.00M | 53.25M | 36.83M | 33.58M |
| ShareIssued | 87.00M | 53.25M | 36.83M | 33.58M |
| TotalDebt | 1.61M | 2.23M | 2.48M | 188.00K |
| TangibleBookValue | 162.13M | 121.00M | 116.17M | 149.47M |
| InvestedCapital | 162.13M | 121.00M | 116.17M | 149.47M |
| WorkingCapital | 159.23M | 119.05M | 99.71M | 149.64M |
| NetTangibleAssets | 162.13M | 121.00M | 116.17M | 149.47M |
| CapitalLeaseObligations | 1.61M | 2.23M | 2.48M | 188.00K |
| CommonStockEquity | 162.13M | 121.00M | 116.17M | 149.47M |
| TotalCapitalization | 162.13M | 121.00M | 116.17M | 149.47M |
| TotalEquityGrossMinorityInterest | 162.13M | 121.00M | 116.17M | 149.47M |
| StockholdersEquity | 162.13M | 121.00M | 116.17M | 149.47M |
| GainsLossesNotAffectingRetainedEarnings | -7.00K | -79.00K | -351.00K | 0.00 |
| OtherEquityAdjustments | -7.00K | -79.00K | -351.00K | |
| RetainedEarnings | -403.86M | -329.44M | -260.99M | -209.20M |
| AdditionalPaidInCapital | 565.90M | 450.47M | 377.47M | 358.63M |
| CapitalStock | 87.00K | 53.00K | 37.00K | 34.00K |
| CommonStock | 87.00K | 53.00K | 37.00K | 34.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 13.36M | 11.73M | 7.55M | 2.95M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.45M | 2.13M | 2.35M | 487.00K |
| DerivativeProductLiabilities | 468.00K | 468.00K | 412.00K | 407.00K |
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 983.00K | 1.66M | 1.94M | 80.00K |
| LongTermCapitalLeaseObligation | 983.00K | 1.66M | 1.94M | 80.00K |
| LongTermDebt | 13.97M | |||
| CurrentLiabilities | 11.91M | 9.61M | 5.20M | 2.46M |
| CurrentDebtAndCapitalLeaseObligation | 632.00K | 568.00K | 541.00K | 108.00K |
| CurrentCapitalLeaseObligation | 632.00K | 568.00K | 541.00K | 108.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.27M | 1.81M | 883.00K | 0.00 |
| PayablesAndAccruedExpenses | 9.01M | 7.23M | 3.78M | 2.35M |
| CurrentAccruedExpenses | 3.20M | 2.33M | 507.00K | 1.22M |
| Payables | 5.81M | 4.90M | 3.27M | 1.13M |
| AccountsPayable | 5.81M | 4.90M | 3.27M | 1.13M |
| TotalAssets | 175.49M | 132.74M | 123.72M | 152.42M |
| TotalNonCurrentAssets | 4.34M | 4.08M | 18.81M | 316.00K |
| OtherNonCurrentAssets | 2.92M | 1.84M | 148.00K | 148.00K |
| NonCurrentPrepaidAssets | 148.00K | 148.00K | 191.00K | |
| NonCurrentDeferredAssets | 191.00K | |||
| InvestmentsAndAdvances | 0.00 | 263.00K | 16.47M | 0.00 |
| InvestmentinFinancialAssets | 0.00 | 263.00K | 16.47M | 0.00 |
| HeldToMaturitySecurities | 0.00 | 263.00K | 16.47M | 0.00 |
| NetPPE | 1.42M | 1.98M | 2.19M | 168.00K |
| AccumulatedDepreciation | -138.00K | -107.00K | -71.00K | -40.00K |
| GrossPPE | 1.56M | 2.09M | 2.26M | 208.00K |
| OtherProperties | 396.00K | |||
| MachineryFurnitureEquipment | 210.00K | 210.00K | 210.00K | 56.00K |
| BuildingsAndImprovements | 1.35M | 1.88M | 2.05M | 152.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 171.15M | 128.65M | 104.91M | 152.10M |
| OtherCurrentAssets | 3.29M | 1.78M | 3.01M | 1.69M |
| PrepaidAssets | 3.01M | 1.69M | 946.00K | |
| CashCashEquivalentsAndShortTermInvestments | 167.86M | 126.87M | 101.90M | 150.41M |
| OtherShortTermInvestments | 73.75M | 56.48M | 85.86M | 0.00 |
| CashAndCashEquivalents | 94.11M | 70.40M | 16.04M | 150.41M |
| CashEquivalents | 89.06M | 61.25M | 9.95M | |
| CashFinancial | 5.05M | 9.15M | 6.09M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -69.08M | -57.37M | -44.63M | -39.62M |
| RepaymentOfDebt | 0.00 | -16.01M | 0.00 | |
| IssuanceOfDebt | 0.00 | 15.00M | ||
| IssuanceOfCapitalStock | 86.40M | 49.02M | 12.33M | 122.82M |
| CapitalExpenditure | -153.00K | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 1.49M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 94.11M | 70.40M | 16.04M | 150.41M |
| BeginningCashPosition | 70.40M | 16.04M | 150.41M | 41.05M |
| ChangesInCash | 23.71M | 54.36M | -134.37M | 109.36M |
| FinancingCashFlow | 107.33M | 63.03M | 11.57M | 148.98M |
| CashFlowFromContinuingFinancingActivities | 107.33M | 63.03M | 11.57M | 148.98M |
| NetOtherFinancingCharges | -1.06M | -318.00K | -759.00K | -3.97M |
| ProceedsFromStockOptionExercised | 21.98M | 14.33M | 0.00 | 46.14M |
| NetPreferredStockIssuance | 10.78M | 0.00 | ||
| PreferredStockIssuance | 10.78M | 0.00 | ||
| NetCommonStockIssuance | 86.40M | 49.02M | 12.33M | 122.82M |
| CommonStockIssuance | 86.40M | 49.02M | 12.33M | 122.82M |
| NetIssuancePaymentsOfDebt | 0.00 | -16.01M | 15.00M | |
| NetLongTermDebtIssuance | 0.00 | -16.01M | 15.00M | |
| LongTermDebtPayments | 0.00 | -16.01M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 15.00M | ||
| InvestingCashFlow | -14.54M | 48.70M | -101.46M | 0.00 |
| CashFlowFromContinuingInvestingActivities | -14.54M | 48.70M | -101.46M | 0.00 |
| NetInvestmentPurchaseAndSale | -14.54M | 48.70M | -101.31M | 0.00 |
| SaleOfInvestment | 113.60M | 115.10M | 6.00M | 0.00 |
| PurchaseOfInvestment | -128.14M | -66.40M | -107.31M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -153.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -153.00K | 0.00 | |
| OperatingCashFlow | -69.08M | -57.37M | -44.48M | -39.62M |
| CashFlowFromContinuingOperatingActivities | -69.08M | -57.37M | -44.48M | -39.62M |
| ChangeInWorkingCapital | 47.00K | 3.10M | 1.02M | -642.00K |
| ChangeInPayablesAndAccruedExpense | 2.14M | 3.23M | 2.34M | 218.00K |
| ChangeInAccruedExpense | 721.00K | 2.15M | 205.00K | 229.00K |
| ChangeInPayable | 1.42M | 1.08M | 2.14M | -11.00K |
| ChangeInAccountPayable | 1.42M | 1.08M | 2.14M | -11.00K |
| ChangeInPrepaidAssets | -2.10M | -129.00K | -1.32M | -860.00K |
| OtherNonCashItems | 532.00K | 526.00K | 352.00K | 667.00K |
| StockBasedCompensation | 7.12M | 7.36M | 7.27M | 3.69M |
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -2.39M | -2.84M | -1.37M | 0.00 |
| DepreciationAmortizationDepletion | 31.00K | 36.00K | 30.00K | 13.00K |
| DepreciationAndAmortization | 31.00K | 36.00K | 30.00K | 13.00K |
| Depreciation | 31.00K | 36.00K | 30.00K | |
| OperatingGainsLosses | 2.91M | 5.00K | -2.28M | -1.78M |
| GainLossOnInvestmentSecurities | 2.91M | 5.00K | -4.05M | -1.78M |
| NetIncomeFromContinuingOperations | -74.41M | -68.46M | -51.79M | -41.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RZLT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|